Check-Cap (NASDAQ:CHEK) Coverage Initiated at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Trading Down 7.4 %

Shares of NASDAQ:CHEK opened at $1.00 on Friday. The firm’s 50 day moving average is $1.47 and its two-hundred day moving average is $1.87. Check-Cap has a 52 week low of $1.00 and a 52 week high of $3.85. The firm has a market capitalization of $5.85 million, a P/E ratio of -0.33 and a beta of 0.39.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.